Brent Siler

Cooley advised the underwriters on Apellis Pharmaceuticals’ $402.5 million follow-on offering of 8,563,830 shares of common stock at a price to the public of $47.00 per share. Apellis is a global biopharmaceutical company committed to leveraging courageous science, creativity and compassion to deliver life-changing therapies. Partners Div Gupta and Brent Siler led the Cooley team.

Cooley advised MaxCyte on its $201.8 million initial public offering of 15,525,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. MaxCyte, whose securities now trade on the Nasdaq Global Select Market under the symbol “MXCT,” also trades on the London Stock Exchange under the symbols "MXCT" and "MXCN." MaxCyte is a leading provider of cell-engineering platform technologies. Partners Christian Plaza, Brian Leaf and Claire Keast-Butler led the Cooley team.

Cooley advised the underwriters on Verve Therapeutics’ $306.7 million initial public offering of 16,141,157 shares of common stock. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Verve Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol VERV, is a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene-editing medicines. Partners Brent Siler, Div Gupta and Richard Segal led the Cooley team.

Cooley advised the underwriters on Werewolf Therapeutics’ $120 million initial public offering of 7,500,000 shares of common stock. Jefferies, SVB Leerink and Evercore Group acted as joint book-running managers. Werewolf Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol HOWL, is an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Partners Brent Siler, Madison Jones and Div Gupta led the Cooley team.

Cooley advised Instil Bio on its $368 million initial public offering of 18,400,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Instil Bio, whose securities now trade on the Nasdaq Global Market under the symbol TIL, is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocytes therapies for the treatment of patients with cancer. Partners Div Gupta, Madison Jones and Brent Siler led the Cooley team.